cenderitide
Peptideexperimental
Cenderitide is a natriuretic peptide developed by the Mayo Clinic as a potential treatment for heart failure. Cenderitide is created by the fusion of the 15 amino acid C-terminus of the snake venom dendroaspis natriuretic peptide (DNP) with the full C-type natriuretic peptide (CNP) structure. This peptide chimera is a dual activator of the natriuretic peptide receptors NPR-A and NPR-B and therefore exhibits the natriuretic and diuretic properties of DNP, as well as the antiproliferative and antifibrotic properties of CNP. — Wikipedia
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2011 (NCT01316432)
Timeline
Indications
Mechanism of action
- Atrial natriuretic factorACTIVATOR
NPPA activator
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaCenderitide ↗
- ChEMBLCHEMBL2108721 ↗
- WikipediaCD-NP ↗
Also known as
- cd-np
- cd-np
- cenderitide
- cenderitide
- cenderitide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03091998 | Phase 1 | May 1, 2017 | Mayo Clinic |
| NCT02603614 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2015 | Capricor Inc. |
| NCT02359227 | Phase 2 | Jan 1, 2015 | Capricor Inc., Orange County Research Center |
| NCT01316432 | Phase 1 | May 1, 2011 | Integrium, Nile Therapeutics |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Capricor Inc. | For profit | 2 | 2 | 1 | 2015 |
| Integrium | For profit | 1 | 0 | 1 | 2011 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Nile Therapeutics | For profit | 1 | 1 | 1 | 2011 |
| Orange County Research Center | Academic/Hospital | 1 | 0 | 1 | 2015 |
5 organizations
Page 1 / 1